HIV-1-infection Completed Phase 3 Trials for Abacavir (DB01048)

Also known as: HIV -1 Infection / HIV1 Infection / HIV-I Infection / HIV 1 Infection / Human Immunodeficiency Virus Type 1 (HIV-1) Infection / Human Immunodeficiency Virus I Infection / Infection, Human Immunodeficiency Virus I / HIV-1 Infections / HIV-1 Infection / [X]Human immunodeficiency virus disease (disorder) / Human immunodeficiency virus [HIV] disease / [X]Unspecified human immunodeficiency virus [HIV] disease (disorder) / HIV disease / (AIDS) or (HIV infection) / HTLV-III/LAV infection -RETIRED- / HIV infection NOS / Human immunodeficiency virus syndrome / Human immunodeficiency virus infection, unspecified / HIV Infections / HIV infection / Human immunodeficiency virus infection (disorder)

IndicationStatusPhase
DBCOND0054009 (HIV-1-infection)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02603120Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically SuppressedTreatment
NCT02605954Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected AdultsTreatment
NCT021573114 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV PatientsTreatment
NCT01352715Study of Options for Second-Line Effective Combination Therapy (SELECT)Treatment
NCT00044577New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected SubjectsTreatment
NCT00046176A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced PatientsTreatment
NCT00440947Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 InfectionTreatment
NCT01263015A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)Treatment